痳病:パイプラインレビュー2019下半期

【英語タイトル】Gonorrhea - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120320)・商品コード:GDATA9120320
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:108
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Gonorrhea – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea – Pipeline Review, H2 2019, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Gonorrhea – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 4, 9, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gonorrhea – Overview
Gonorrhea – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gonorrhea – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gonorrhea – Companies Involved in Therapeutics Development
Biolytics Pharma
Debiopharm International SA
Entasis Therapeutics Inc
Evofem Biosciences Inc
GlaxoSmithKline Plc
Hsiri Therapeutics LLC
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Paratek Pharmaceuticals Inc
Pharmiva AB
Redx Pharma Plc
Gonorrhea – Drug Profiles
Amphora – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCP-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Gonorrhea – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Debio-1453 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edodekin alfa SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein for Gonorrhea – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepotidacin mesylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gonorrhea vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKL-35 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-4132 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGoXIM – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-2S – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXP-2382 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Gyrase and Topoisomerase IV for Gonorrhea – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PBP2 for Gonorrhea – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Tubulin for Gonorrhea and Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zoliflodacin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gonorrhea – Dormant Projects
Gonorrhea – Discontinued Products
Gonorrhea – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gonorrhea, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Gonorrhea - Pipeline by Biolytics Pharma, H2 2019
Gonorrhea - Pipeline by Debiopharm International SA, H2 2019
Gonorrhea - Pipeline by Entasis Therapeutics Inc, H2 2019
Gonorrhea - Pipeline by Evofem Biosciences Inc, H2 2019
Gonorrhea - Pipeline by GlaxoSmithKline Plc, H2 2019
Gonorrhea - Pipeline by Hsiri Therapeutics LLC, H2 2019
Gonorrhea - Pipeline by Melinta Therapeutics Inc, H2 2019
Gonorrhea - Pipeline by Merck & Co Inc, H2 2019
Gonorrhea - Pipeline by Microbiotix Inc, H2 2019
Gonorrhea - Pipeline by Paratek Pharmaceuticals Inc, H2 2019
Gonorrhea - Pipeline by Pharmiva AB, H2 2019
Gonorrhea - Pipeline by Redx Pharma Plc, H2 2019
Gonorrhea - Dormant Projects, H2 2019
Gonorrhea - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Gonorrhea, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

【掲載企業】

Biolytics Pharma
Debiopharm International SA
Entasis Therapeutics Inc
Evofem Biosciences Inc
GlaxoSmithKline Plc
Hsiri Therapeutics LLC
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Paratek Pharmaceuticals Inc
Pharmiva AB
Redx Pharma Plc

★調査レポート[痳病:パイプラインレビュー2019下半期] (コード:GDATA9120320)販売に関する免責事項を必ずご確認ください。
★調査レポート[痳病:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆